Stephen Smart, MD
Allergy & Immunology · Peoria, ILNPI 1265429625
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $28,135 of the $41,264 with a category attached, or 68.2%. AstraZeneca accounts for 66.5% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2022 at $18,937 and has fallen 89.7% since, to $1,945 in 2025.
Across 644 payments — averaging $64.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$27K
- Boehringer Ingelheim$4K
- GSK$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Sanofi$1K
- CSL Behring$899
- plus $5K from 31 others
What the payments were for
- Consulting fees$1920%
- Speaking & faculty fees$28,13568%
- Travel & lodging$3191%
- Food & beverage$12,42030%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 102 | $27,427 |
| Boehringer Ingelheim | 43 | $4,227 |
| GSK | 112 | $1,709 |
| Takeda Pharmaceuticals U.S.A., Inc. | 49 | $1,075 |
| Sanofi | 49 | $1,032 |
| CSL Behring | 49 | $899 |
| Regeneron Healthcare Solutions, Inc. | 30 | $857 |
| Pfizer | 33 | $546 |
| Genentech USA, Inc. | 16 | $334 |
| Grifols USA, LLC | 16 | $333 |
| Novartis | 15 | $315 |
| Amgen(2 entities) | 15 | $308 |
| Teva Pharmaceuticals USA, Inc. | 21 | $293 |
| Optinose US, Inc. | 17 | $281 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $188 |
| Octapharma USA, Inc. | 4 | $172 |
| Kaleo, Inc. | 9 | $160 |
| Phadia US Inc. | 8 | $153 |
| Alk-abello, Inc | 8 | $136 |
| Pharming Healthcare, Inc. | 4 | $110 |
| Biocryst US Sales Co., LLC | 4 | $93 |
| Greer Laboratories, Inc. | 4 | $85 |
| ADMA Biomanufacturing LLC | 4 | $73 |
| Incyte Corporation | 3 | $65 |
| LEO Pharma Inc. | 3 | $62 |
| Verona Pharma, Inc. | 3 | $57 |
| Aimmune Therapeutics, Inc. | 2 | $41 |
| Shire North American Group Inc | 2 | $40 |
| Merck | 2 | $39 |
| Blueprint Medicines Corporation | 1 | $26 |
| Ionis Pharmaceuticals, Inc. | 1 | $25 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 3 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Biocryst Pharmaceuticals, Inc. | 1 | $13 |
| Organon | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,264 in reported general payments places this provider in the 85th percentile of 161 allergy & immunology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 84 | $342,058 |
| TezspireTezepelumab-Ekko | 20 | $86,227 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 69 | $50,566 |
| Spiriva RespimatTiotropium Bromide | 56 | $39,994 |
| Breo ElliptaFluticasone/Vilanterol | 73 | $38,334 |
| DuleraMometasone/Formoterol | 33 | $16,604 |
| Arnuity ElliptaFluticasone Furoate | 53 | $12,506 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $12,009 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $10,561 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $10,462 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 54 | $9,839 |
| XhanceFluticasone Propionate | 15 | $9,654 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $9,392 |
| Atrovent HfaIpratropium Bromide | 14 | $6,601 |
| Fluticasone Propionate HfaFluticasone Propionate | 24 | $5,810 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,709 | $111,966212 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere, Pulmicort Flexhaler | $27,427 | $109,31783 claims |
| Boehringer IngelheimSpiriva Respimat | $4,227 | $39,99456 claims |
| MerckDulera | $39 | $16,60433 claims |
| Optinose US, Inc.Xhance | $281 | $9,65415 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $293 | $5,30613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 161 allergy & immunology providers in Illinois.
Other allergy & immunology in Peoria
- Penelope EwbankPeoria$62K
- Dareen SiriNormal$1.5M
- Priya BansalSaint Charles$1.3M
- Anju PetersChicago$563K
- Giselle MosnaimChicago$331K
- Patrick WinShiloh$258K
- Amanda SalihChicago$160K
- Rebecca HoffmanWilmette$160K
- Juanita MoraChicago$147K
- Sonali MajmudarAlgonquin$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.